Operating profit before amortization: Qiagen NV (QGEN)
The absolute operating profit metric on GURU.Markets contains data on Qiagen N.V. (QGEN), a molecular diagnostics innovator creating the foundation for personalized medicine. The indispensable nature of their nucleic acid isolation kits ensures a stable monopoly position in forensics. Meanwhile, the 734.55 metric confirms the current level of profitability, which is based on high-margin sales of test systems and reagents for research laboratories.
%20Operating%20profit%20before%20deduction%20of%20amortization&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_QGEN_-_Qiagen-N.V._-_Operating-profit-before-deduction-of-amortization "QGEN (Qiagen Group) Income before deduction of interest, taxes and amortization history from 11/23/2025 to 11/14/2026 | 👁️GURU.Markets👁️")
Qiagen - analytical breakdowns and key metrics (QGEN)
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- company total debt and liquidity indicators:
- earnings and market ratios statistics:
QGEN - Net Profit|Expected Net Profit Qiagen N.V.|QGEN - Price to Earnings Ratio|Price to Future Earnings Ratio qiagen.com|QGEN - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Qiagen|QGEN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Qiagen|QGEN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth qiagen.com|QGEN - Earnings per share growth in current year|Net earnings per one share growth forecast for next year Qiagen N.V.
- sales and revenue data:
Fundamental company valuation:QGEN Qiagen Corp
Qiagen N.V. (QGEN) generates its primary revenue through the supply of reagents and equipment for nucleic acid analysis. This indicator captures daily operating profit, adjusted for depreciation and taxes. By analyzing the EBITDA timeline, an investor assesses the efficiency of the company's commercial asset utilization. Growth in this metric confirms the scaling of consumables sales within the clinical sector. Stable dynamics reinforce the asset's status as a fundamentally resilient business.
Competitors of Qiagen N.V. (QGEN)
Tempus (TEM) - Profit before interest, taxes and amortization|IONS - Profit before payment of interest, taxes and amortization|RGEN (repligen.com) - Operating profit before amortization|RNA (Avidity Biosciences, Inc.) - Operating profit before deduction of amortization|CRISPR Therapeutics Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sema4|Operating profit before amortization RARE (Ultragenyx Corp)|Operating profit before deduction of amortization BEAM (Beam Therapeutics Inc.)|Operating income before deduction of amortization sarepta.com|Twist Bioscience, Inc. - Operating profit before deduction of amortization|10x Genomics Inc - Profit before payment of interest, taxes and amortization|NTLA: Operating profit before deduction of amortization|Operating income before deduction of amortization Stoke Corp STOK|BioLife Solutions, Inc. (BLFS) - Profit before payment of interest, taxes and amortization|Operating profit before depreciation charges wavelifesciences.com WVE|MAZE (Maze Therapeutics) - Operating profit EBITDA|SION - Operating profit before depreciation charges|Operating profit EBITDA PRME|TSHA - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization uniQure N.V. QURE|MGTX: Operating profit before amortization|REGENXBIO - Operating profit EBITDA|SLDB (Solid Biosciences Inc) - Operating profit before amortization|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PACB|BNTC (Benitec Biopharma Inc.) - Operating profit EBITDA|Operating profit EBITDA designtx.com|Profit before payment of interest, taxes and amortization Rocket Pharmaceuticals, Inc. (RCKT)|4DMT (FDMT) - Operating profit before depreciation charges|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|Operating income before deduction of amortization Korro Bio Inc. (KRRO)|Editas Medicine, Inc. - Operating profit EBITDA|SLN - Operating profit EBITDA|PRQR: Operating profit EBITDA|Operating profit before depreciation charges Codexis CDXS|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Generation Bio - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BOLD|XCUR - Profit before payment of interest, taxes and amortization|IMNN (Imunon, Inc.) - Operating profit before amortization|PHIO (phiopharma.com) - Operating profit before deduction of amortization|MBIO - Operating income before deduction of amortization|Operating profit before deduction of amortization RNAZ|Profit before payment of interest, taxes and amortization BNGO|Operating profit before deduction of amortization APDN (Applied DNA)|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|Operating profit before depreciation charges omegatherapeutics.com|Singular Genomics - Operating profit EBITDA|Operating profit before depreciation charges Regulus Therapeutics, Inc. (RGLS)|SYRS: Operating profit EBITDA|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
